At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Predictive Value of E-cadherin, β-catenin and SOX4 in Recurrence and/or Progression of Non-muscle Invasive Urinary Bladder Transitional Cell Carcinoma. A Retrospective Study
In Brief
An observational study for Bladder Cancer and Bladder Cancer Recurrence. Completed, enrolled 30 participants across 1 site.
Detailed Summary
Bladder cancer is common tumor in which recurrence and/or progression in patients undergoing TUR has been reported to range between 30% and 80% in patients with NMIBC TCC. With evidence of E-cadherin, β-catenin and SOX4 playing a role in the development of tumors, it manifests as invasion and metastasis. In this study, we hope to develop the correlation regarding the alternation in the expression of E-cadherin, β-catenin and Sox4 in determining the recurrence, progression and up staging and their prognostic value in NMIBC.
Study Details
Timeline
Arms & Interventions
* Inclusion Criteria: 1. The patients were treated with transurethral resection of bladder tumor finally diagnosed with NMIBC TCC by pathological examination. 2. The controls were normal bladder tissues. Or patients diagnosed with cystitis or dysplasia on pathological examination * Exclusion Criteria: 1. Age at the time of cancer diagnosis \> 70 years 2. Patients diagnosed with MIBC 3. Patients with concomitant upper urinary tracts tumors 4. Patients with concomitant prostatic tumors 5. Patients diagnosed with TCC T1 who did not received full induction, or maintenance doses BCG 6. Patients showed BCG toxicity signs 7. Patients diagnosed with TCC T1 who did not underwent 2nd look TURBT 8. Patients with known genetic/congenital disorder that may interfere with/or increase risk of BC; * Bladder exstrophy. * Rb1: An altered form of Rb1, retinoblastoma gene, is associated with cancer of the eye in infants,